Format

Send to

Choose Destination
Acta Biochim Biophys Sin (Shanghai). 2019 Sep 13. pii: gmz093. doi: 10.1093/abbs/gmz093. [Epub ahead of print]

An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.

Author information

1
Department of Second Pulmonary Medicine, The Third Hospital Affiliated to the Xinjiang Medical University, Urumqi 830011, China.
2
Department of Anesthesiology, The Third Hospital Affiliated to the Xinjiang Medical University, Urumqi 830011, China.
3
Department of Lymphoma and Breast Cancer Internal Medicine, The Third Hospital Affiliated to the Xinjiang Medical University, Urumqi 830011, China.

Abstract

The destruction of proteins via the ubiquitin-proteasome system is a multi-step, complex process involving polyubiquitination of substrate proteins, followed by proteolytic degradation by the macromolecular 26S proteasome complex. Inhibitors of the proteasome promote the accumulation of proteins that are deleterious to cell survival and are promising anticancer agents. Oprozomib (OPZ), an oral second-generation proteasome inhibitor, has been shown to inhibit the growth of several cancers in preclinical and clinical trials, including multiple myeloma and head and neck cancers, but its effects on lung cancer has not yet been determined. In this study, we evaluated the inhibitory effects of OPZ on lung cancer cell lines in vitro. The results showed that OPZ significantly suppressed cell proliferation and strongly induced apoptosis in both tested lung cancer cells independent of p53 expression. OPZ was able to cause obvious caspase 3 and PARP cleavages and stabilize p53 and its transcriptional targets p21, PUMA, and Noxa. Moreover, OPZ was capable of sensitizing lung cancer cells to the conventional chemotherapeutic drug cisplatin. Our study provides preclinical data and sheds light on the potential applications of proteasome inhibitor OPZ in lung cancer treatment.

KEYWORDS:

antitumor efficacy; cisplatin; lung cancer cell; oprozomib; second-generation proteasome inhibitor

PMID:
31518420
DOI:
10.1093/abbs/gmz093

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center